Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy
A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate.
All Posts in "News Team"
Philips raises curtain on next-gen helium-sealed MRI scanner
Philips unveiled the next generation of its MRI scanner, with sealed magnets that do not need to be recharged with liquid helium coolant.
Pyxis’ shares tumble after early ADC readout in solid tumors fails to spark inspiration: analyst
While one might expect a positive readout from a biotech’s lead candidate to boost the company’s stock price, Pyxis Oncology’s shares—which have tumbled more than 40% this week—tell a different story.
Flagship-backed Sonata says sayonara to CEO, trims crew by 20 staffers
After two and a half years at sea, Flagship Pioneering-backed cell signaling company Sonata Therapeutics is whittling down its crew by about 20 employees, a company spokesperson confirmed to Fierce Biotech in a Nov. 21 email.
Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment
VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.
BD teams up with MD Anderson, Su Clinica to study HPV self-collection tests in underserved Texas communities
After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits for HPV testing will improve cervical cancer screening rates among underserved communities in southern Texas.
After ProfoundBio buy, Genmab open to more M&A if it makes ‘strategic sense,’ CFO says
LONDON—It’s been a big year for Genmab. While celebrating its 25th anniversary, the cancer-focused biopharma hasn’t rested on its laurels—securing another approval for the AbbVie-partnered Epkinly, scoring its first M&A win and slowly moving from a partner-based to an asset owner-focused model.
Enveda raises $130M series C to take more AI-discovered compounds into the clinic
Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a $130 million series C fundraising round.
Intuitive Surgical stock surges 10% amid da Vinci 5 demand, with full rollout set for 2025
Earlier this year, Intuitive Surgical warned that supplies may be tight in the months ahead as it continues to roll out the latest iteration of its da Vinci robot. And, while the company has made some gains—installing some 110 da Vinci 5 systems in the third quarter of this year, versus 70 in the quarter prior—Intuitive held to its previous timeline, saying it plans to have production scaled up and running up for a broader launch in mid-2025.
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients.
Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy
Philips raises curtain on next-gen helium-sealed MRI scanner
Pyxis’ shares tumble after early ADC readout in solid tumors fails to spark inspiration: analyst
Flagship-backed Sonata says sayonara to CEO, trims crew by 20 staffers
Weekly Market Review – February 8, 2025
Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment
BD teams up with MD Anderson, Su Clinica to study HPV self-collection tests in underserved Texas communities
After ProfoundBio buy, Genmab open to more M&A if it makes ‘strategic sense,’ CFO says
Enveda raises $130M series C to take more AI-discovered compounds into the clinic
Intuitive Surgical stock surges 10% amid da Vinci 5 demand, with full rollout set for 2025